CURRENT STATUS OF EXPOSED MARSHALLESE

I	Young Rongelapese, 0-10 years ATE. Dose: 175 rad + (600-1400) rem.		19
	a. Normal.	2	
	b. Hypothyroid + Thyroid therapy.	3	
	c. Treated by Surgery (Nodularity).	14	
	(Adenomatous Goiter 3)		
	(Hurthle Cell Tumor 1)		
	(Malignant Papillary Adenoma 1)		
II	Young Ailinginae, 0-10 years ATE. Normal. Dose: 69 rad.		6
III	Adult Rongelapese ATE. Dose: 175 rad + 160 rem.		34
	a. Papillary Carcinoma excised, age 41.	1	
	b. Invasive Adenoma.	1	
IV	Adult Ailinginae ATE. Dose: 69 rad.		8
V	Adult and Young Utirikese ATE. Dose: 8 rad.		120
	a. Malignant Follicular Adenoma excised.	1	
VI	Control Populations - Ebeye, Majuro, Rongelap, Utirik		200
	a. Nodular Goiter.	1	

43515

BEST COPY AVAILABLE

THYROID DISEASE IN MARSHALLESE

AGE AT EXPOSURE	THYROID DOSE (RADS)	THYROID NODULES	SURGERY	MALIGNANT
IN UTERO				
RONGELAP	~175	33% (1/3)	1	0
AILINGINAE	~49	0 (0/1)	0	0
< 10 YEARS				
RONGELAP	810-1160	89% (17/19)*	15	1
AILINGINAE	[illegible]	33% (2/6)	1	0
UTIRIK	60-90	2% (1/58)	0	0
CONTROLS	[illegible]	1% (1/92)	0	0
> 10 YEARS				
RONGELAP	[illegible]	11% (5/45)	4	2
AILINGINAE	135-190	33% (4/12)	3	0
UTIRIK	[illegible]	6% (6/99)	4	1
CONTROLS	[illegible]	3% (13/239)	3	0

*INCLUDES TWO CASES OF HYPOTHYROIDISM WITHOUT NODULES.